| Revenue growth | 33% YoY growth in Q2 FY27. |
|---|---|
| Margins | EBITDA margin expanded 720 bps YoY to 18.4% overall. |
| Demand visibility | Strong, especially in regulated markets contributing 78% of base revenue. |
| Management confidence | High; cited 'best quarter in five years' across all segments. |
Growth
Overall revenue rose 33% YoY to INR 4,178 Mn. EBITDA grew 118% YoY to INR 769 Mn.
Outlook
Net debt to EBITDA improved to 1.8x. Strategic review of Ibuprofen business expected within 12 weeks.
Risks
Inflationary pressure on raw materials and solvents persists, linked to the West Asia crisis.
Last quarter's promises, checked
Delivered
- Ibuprofen strategic review by H1 FY27 → Completed/Ongoing as promised (= BEAT)
- Net debt reduction → INR 1,141 Mn reduction in H1 vs planned glide path (= BEAT)
- Base business EBITDA margin ~25% → Trajectory sustained/exceeded (= BEAT)
Partly delivered
- 10% revenue growth guide → 33% growth achieved (Significantly exceeded guide) (= BEAT)
Investor Presentation filed with NSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹653.80
- Market cap
- ₹3,149 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 85.3×Sector 46.1×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹28.5 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences will issue a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up rights equity shares regarding outstanding call money payments.